Lexicon Pharmaceutical’s investigative agent LX1032 has been granted fast-track status by the United States Food and Drug Administration (FDA).
LX1032 is an inhibitor of tryptophan hydroxylase (HTP), a target identified through the Genome5000™ program. Excessive levels of serotonin have been associated with carcinoid syndrome symptoms, and HTP is a rate-limiting enzyme in the synthesis of serotonin. Preclinical studies have demonstrated that LX1032 reduced peripheral serotonin and urinary 5HIAA (a breakdown product of serotonin) without affecting serotonin levels in the brain.
LX1032 has completed Phase Ia studies; Lexicon is awaiting results.
Liquid Biopsy Detects Disease Progression Much Earlier Than Imaging
What if a simple blood test could quickly determine when chemotherapy was ineffective and prevent its unnecessary use?